 MELBOURNE, Australia, Aug. 4, 2021 PRNewswire -- Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Office USPTO has issued a Notice of Allowance for Alteritys patent application No. 17239,375. 